New insights into the safety of CBD: An in-depth look at the systematic review study by Kaplan (2023)”

Update on Cannabidiol Clinical Toxicity and Adverse Effects: a Systematic Review (Kaplan, 2023)

Cannabidiol (CBD), a non-psychoactive substance derived from the cannabis plant, has received increasing attention in medical research and among the public in recent years. The question of potential side effects and toxic effects remains a major concern for consumers and healthcare professionals, although many highlight the health benefits of CBD. “Update on Cannabidiol Clinical Toxicity and Adverse Effects,” a recent 2023 systematic review by Kaplan published on SciSpace, provides a detailed overview of the clinical toxicity and adverse effects of CBD. This article explains the main findings of this review and discusses the significance for users and researchers seeking thorough information on the safety of CBD.

 

Background

In recent years, cannabidiol (CBD), a non-psychoactive component of the cannabis plant, has been medical research and therapy. Despite its increasing popularity, the safety of CBD has been limited and inconsistent. In 2019, the scientific literature on CBD-related toxicity and adverse events (AEs) was reviewed, increasing interest in systematically investigating these aspects.

 

Objective

The aim of the study, along with new findings by Emin Kaplan (2023), was to conduct a comprehensive and updated assessment of the toxicities and adverse effects associated with the use of CBD in humans. Given the rapid increase in clinical trials investigating CBD, this presented an opportunity to review more recent data and further investigate CBD safety.

 

Methodology

The PRISMA guidelines were followed in the systematic review to identify studies published between February 2019 and September 2022 that addressed toxicity or AEs related to CBD. PubMed, Cochrane and Embase were used as key scientific databases. The authors obtained information on study design, demographic characteristics of participants, dosage of CBD, duration of treatment, concomitant medications and AEs that occurred.

 

Results

The analysis included 51 study reports covering a wide range of medical applications, primarily in neurological areas such as the treatment of treatment-resistant epilepsy. Other areas investigated included pervasive psychopathological conditions such as substance use disorders, chronic psychoses, and anxiety disorders. The majority of reported adverse events were mild to moderate in severity. The most common adverse events included diarrhea, drowsiness, sedation, and upper respiratory tract disturbances. The study found that severe adverse events were rare, especially in the absence of co-administration. The reports of severe adverse events highlighted the need to carefully monitor interactions with other drug classes, particularly clobazam and valproate.

 

Conclusions

The evaluation included 51 review studies with a wide range of medical applications, primarily in neurological fields such as the treatment of treatment-resistant epilepsy. Other fields investigated included psychopathological disorders such as anxiety disorders, chronic psychoses, and substance use disorders. The vast majority of reported AEs were mild to moderate in severity. The most common AEs were diarrhea, somnolence, sedation, and respiratory disturbances. The study found that severe AEs were rare, especially when co-administered with other medications. Reports of severe AEs underscored the importance of careful monitoring for interactions with other drug classes, especially clobazam and valproate.

 

outlook

Kaplan's (2023) study makes a significant contribution to improving the understanding of CBD's safety profile and provides a solid foundation for future research. It is important that the interactions, efficacy, and safety of CBD continue to be carefully studied as it is used in numerous therapeutic applications. The results of this study are particularly important for physicians and scientists considering CBD as a treatment option.

This in-depth review highlights that while CBD has promising therapeutic potential, close monitoring and additional research are needed to fully understand and implement its safety and effectiveness.

 

 

Result	Description	affected population	Notes
frequency of side effects	Most side effects were mild to moderate in severity.	study participants in various clinical trials	Includes neurological conditions and psychopathological disorders.
type of side effects	The most common side effects were diarrhea, drowsiness, sedation and upper respiratory tract disorders.	-	Important information for monitoring and management during clinical use of CBD.
Severe side effects	Few serious side effects have been reported, particularly when co-medicated with clobazam and valproate.	Participants who received other medications in addition to CBD	Indication of the need to monitor interactions with other medications.
Compatibility	CBD was rated as well tolerated.	Children and adults	Supports further research and use of CBD in therapeutic contexts.